Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$16.92 USD

16.92
1,422,417

-0.30 (-1.74%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $16.90 -0.02 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.

Zacks Equity Research

AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.

Zacks Equity Research

AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AMN Healthcare (AMN) delivered earnings and revenue surprises of 11.82% and 4.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Device Stocks Earnings on Aug 4: BDX, ABMD, AMN & DOCS

by Debanjana Dey

The Medical Device companies' Q2 results are likely to reflect strength in customer demand. Let's see how BDX, ABMD, AMN and DOCS are placed ahead of their earnings releases.

Zacks Equity Research

AMN Healthcare (AMN) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

AMN Healthcare's (AMN) second-quarter results are likely to reflect solid demand across all its segments.

Zacks Equity Research

AMN Healthcare Services (AMN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed the most recent trading day at $113.34, moving +0.27% from the previous trading session.

Zacks Equity Research

Here's Why You Should Hold on to OPKO Health (OPK) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and a few strategic agreements.

Zacks Equity Research

Here's Why You Should Hold On to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

Zacks Equity Research

Potbelly's and Rio Tinto have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Potbelly's and Rio Tinto have been highlighted as Zacks Bull and Bear of the Day.

Zacks Equity Research

Elevance Health (ELV) Q2 Earnings Beat on Higher Premiums

by Zacks Equity Research

Elevance Health (ELV) hikes adjusted net income estimate for this year to more than $28.70 per share.

Zacks Equity Research

LabCorp (LH) to Offer New Test Report for Venom Allergy Testing

by Zacks Equity Research

LabCorp's (LH) newly-launched interpretative venom allergy report will inform enhanced treatment decisions in case of venomous insect stings.

Zacks Equity Research

QIAGEN (QGEN) QCI's Robust Adoption to Enhance Patient Outcome

by Zacks Equity Research

QIAGEN's (QGEN) QCI platform is expected to significantly streamline NGS data analysis and variant interpretation, and enable swift and confident shift by users from raw NGS data to clinical report.

Zacks Equity Research

Is Aziyo Biologics (AZYO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aziyo Biologics, Inc. (AZYO) and AMN Healthcare Services (AMN) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Potential to Fight Recession Risk

by Indrajit Bandyopadhyay

The decline in U.S. GDP during the first quarter and 26% decline in the S&P 500 Index so far this year fuel the risk of a recession. MCK, PDCO & AMN have the potential to help investors ward off volatility risks going forward.

Zacks Equity Research

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, AMN Healthcare Services (AMN) closed at $122.77, marking a +1.37% move from the previous day.

Zacks Equity Research

Here's Why You Should Retain Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.

Zacks Equity Research

NextGen (NXGN)-InstaMed Ink Deal to Improve Payment Processing

by Zacks Equity Research

NextGen's (NXGN) latest expanded deal with InstaMed is expected to significantly simplify payment methods for both patients and providers.

Zacks Equity Research

3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care.

Zacks Equity Research

Here's Why Momentum in AMN Healthcare (AMN) Should Keep going

by Zacks Equity Research

AMN Healthcare (AMN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Zacks Equity Research

The Zacks Analyst Blog Highlights AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale

by Zacks Equity Research

AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale have been included in this Analyst Blog.

Zacks Equity Research

Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Zacks Equity Research

Alcon's (ALC) Product Launches, Market Recovery Aid Growth

by Zacks Equity Research

Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: AMN Healthcare, Boeing, Clorox, Home Depot in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.

Zacks Equity Research

3 Reasons Why BD (BDX) is a Great Pick For Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.